logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
RVMD
Revolution Medicines, Inc.
187.51
2 x 171.26
2 x 198.27
bid
ask
+
0.23
0.12%
2 @ 06:00 AM
189.24 +1.73 (0.92%)
Ytd135.42%
1y404.19%
182.82
day range
188.46
34.00
52 week range
193.09
Open185.49Prev Close187.28Low182.82High188.46Mkt Cap39.86B
Vol2.08MAvg Vol3.49MEPS-7.12P/EN/AForward P/E-32.99
Beta1.41Short Ratio4.34Inst. Own95.85%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-0550-d Avg153.70200-d Avg100.671yr Est191.05

RVMD News

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
fool.com
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Ab

Revolution Medicines' cancer drugs in development could establish new standards of care in some nich

10 Health Care Stocks With Whale Alerts In Today’s Session
benzinga.com
10 Health Care Stocks With Whale Alerts In Today’s Session

This whale alert can help traders discover the next big trading opportunities. Whales are entities w
benzinga.com
Truist Securities Maintains Buy on Revolution Medicines, Raises Price Target to $210

Truist Securities analyst Gregory Renza maintains Revolution Medicines (NASDAQ:RVMD) with a Buy a
benzinga.com
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $235

Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the

benzinga.com
Revolution Medicines Begins Treating Patients In RASolute 305, Global, Randomized Phase 3 Clinical T

Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patie
benzinga.com
$1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth This Much Today
benzinga.com
Evercore ISI Group Maintains Outperform on Revolution Medicines, Raises Price Target to $220

Evercore ISI Group analyst Cory Kasimov maintains Revolution Medicines (NASDAQ:RVMD) with a Outpe
benzinga.com
RBC Capital Maintains Outperform on Revolution Medicines, Raises Price Target to $182

RBC Capital analyst Leonid Timashev maintains Revolution Medicines (NASDAQ:RVMD) with a Outperfor
benzinga.com
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $195

HC Wainwright & Co. analyst Robert Burns maintains Revolution Medicines (NASDAQ:RVMD) with a

benzinga.com
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $195

Oppenheimer analyst Jay Olson maintains Revolution Medicines (NASDAQ:RVMD) with a Outperform and